NASDAQ:AEGR

AEGR (AEGR) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.97
$1.97
50-Day Range
$1.97
$1.97
52-Week Range
$1.23
$10.85
Volume
N/A
Average Volume
635,262 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
AEGR stock logo

About AEGR Stock (NASDAQ:AEGR)

Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).

AEGR Stock News Headlines

Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
Cramer's 'Mad Money' Recap: Next Week's Game Plan
See More Headlines
Receive AEGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AEGR and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/16/2016
Today
4/23/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AEGR
CUSIP
00767E10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

AEGR Stock Analysis - Frequently Asked Questions

How were AEGR's earnings last quarter?

AEGR (NASDAQ:AEGR) posted its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $1.14. The biopharmaceutical company had revenue of $35.70 million for the quarter, compared to analysts' expectations of $43 million. The firm's revenue was down 39.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.55) EPS.

What other stocks do shareholders of AEGR own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AEGR investors own include Allergan (AGN), BioMarin Pharmaceutical (BMRN), Netflix (NFLX), Tesla (TSLA), Ariad Pharmaceuticals (ARIA), Arrowhead Pharmaceuticals (ARWR), Chesapeake Energy (CHKAQ), Chipotle Mexican Grill (CMG) and Gilead Sciences (GILD).

This page (NASDAQ:AEGR) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners